Article Information
- Received May 30, 2003
- Revision received September 4, 2003
- Accepted October 1, 2003
- First published December 3, 2003.
- Version of record published December 3, 2003.
Author Information
- Erwan Bezard1,
- Sandra Dovero1,
- David Belin2,
- Sophie Duconger2,
- Vernice Jackson-Lewis3,
- Serge Przedborski3,
- Pier Vincenzo Piazza2,
- Christian E. Gross1, and
- Mohamed Jaber4
- 1Basal Gang, Centre National de la Recherche Scientifique (CNRS) Unité Mixte de Recherche (UMR) 5543, Université Victor Segalen, 33076 Bordeaux Cedex, France, 2Institut National de la Santé et de la Recherche Médicale 259, Institut François Magendie, 33077 Bordeaux Cedex, France, 3Departments of Neurology and Pathology, Columbia University, New York, New York 10032, and 4CNRS UMR 6558, Université de Poitiers, 86022 Poitiers Cedex, France
Author contributions
Disclosures
- Received May 30, 2003.
- Revision received September 4, 2003.
- Accepted October 1, 2003.
This work was supported by Centre National de la Recherche Scientifique (CNRS); Institut National de la Santé et de la Recherche Médicale; Region Aquitaine; National Institutes of Health and National Institute of Neurological Disorders and Stroke Grants R29 NS37345, RO1 NS38586, RO1 NS42269, and P50 NS38370; United States Department of Defense Grant DAMD 17-99-1-9471; the Parkinson's Disease Foundation; the Lowenstein Foundation; the Lillian Goldman Charitable Trust; the Muscular Dystrophy Association; the Amyotrophic Lateral Sclerosis Association; and Project Amyotrophic Lateral Sclerosis. We give special thanks to M. Cador for helpful advice and to D. Guilloteau for providing the dopamine transporter ligand (PE2I).
Correspondence should be addressed to Mohamed Jaber, Centre National de la Recherche Scientifique Unité Mixte de Recherche 6558, University de Poitiers, 40 Avenue Du Recteur Pineau, 86022 Poiters Cedex, France. E-mail: mohamed.jaber{at}univ-poitiers.fr.
Copyright © 2003 Society for Neuroscience 0270-6474/03/2310999-09$15.00/0